BioMérieux's BioFire Diagnostics acquisition is already producing financial gains

French diagnostics giant bioMérieux closed its $450 million acquisition of Utah's BioFire Diagnostics only in January, but the investment is already beginning to pay off. Earnings during the quarter hit $512.5 million, 3.3% higher than the same period in 2013. BioFire added $19.3 million in quarterly revenues, the company said, mostly from sales generated by its FilmArray Respiratory and Blood Culture Identification tests. BioMérieux said it enjoyed large sales gains in North America, but sales dropped in the Asia Pacific and Latin American markets. As of the end of the first quarter, bioMérieux's debt came in at $44 million, with $35.3 million in net cash on hand. More

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.